Back to Search
Start Over
Clinical pharmacology of benoxaprofen.
- Source :
-
European journal of rheumatology and inflammation [Eur J Rheumatol Inflamm] 1982; Vol. 5 (2), pp. 98-112. - Publication Year :
- 1982
-
Abstract
- Eating does not modify benoxaprofen blood concentrations. Combining benoxaprofen with tolbutamide does not significantly change plasma glucose, insulin, or tolbutamide concentrations. Probenecid, by blocking renal tubular secretion of benoxaprofen, increases the benoxaprofen half-life and decreases its renal clearance and urinary excretion. Excretion rate is halved in patients with severe renal impairment. Hemodialysis inefficiently lowers benoxaprofen plasma concentrations. Neither glomerular nor renal tubular function is affected by benoxaprofen, even after five years of therapy. The incidence in urine of microscopic spheroids (benoxaprofen glucuronide complexes) is related to urinary drug concentration and osmolality; increasing the fluid intake decreases incidence.
- Subjects :
- Adult
Aged
Anti-Inflammatory Agents blood
Anti-Inflammatory Agents urine
Binding, Competitive
Creatinine metabolism
Food
Humans
Hypoglycemic Agents blood
Kidney drug effects
Kidney metabolism
Kidney Tubules metabolism
Middle Aged
Probenecid pharmacology
Propionates blood
Propionates urine
Anti-Inflammatory Agents metabolism
Propionates metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0140-1610
- Volume :
- 5
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- European journal of rheumatology and inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 7084287